Literature DB >> 34298824

Assessing Versatile Machine Learning Models for Glioma Radiogenomic Studies across Hospitals.

Risa K Kawaguchi1,2,3, Masamichi Takahashi4, Mototaka Miyake5, Manabu Kinoshita6, Satoshi Takahashi2,7, Koichi Ichimura8, Ryuji Hamamoto2,7, Yoshitaka Narita4, Jun Sese2,9.   

Abstract

Radiogenomics use non-invasively obtained imaging data, such as magnetic resonance imaging (MRI), to predict critical biomarkers of patients. Developing an accurate machine learning (ML) technique for MRI requires data from hundreds of patients, which cannot be gathered from any single local hospital. Hence, a model universally applicable to multiple cohorts/hospitals is required. We applied various ML and image pre-processing procedures on a glioma dataset from The Cancer Image Archive (TCIA, n = 159). The models that showed a high level of accuracy in predicting glioblastoma or WHO Grade II and III glioma using the TCIA dataset, were then tested for the data from the National Cancer Center Hospital, Japan (NCC, n = 166) whether they could maintain similar levels of high accuracy.
Results: we confirmed that our ML procedure achieved a level of accuracy (AUROC = 0.904) comparable to that shown previously by the deep-learning methods using TCIA. However, when we directly applied the model to the NCC dataset, its AUROC dropped to 0.383. Introduction of standardization and dimension reduction procedures before classification without re-training improved the prediction accuracy obtained using NCC (0.804) without a loss in prediction accuracy for the TCIA dataset. Furthermore, we confirmed the same tendency in a model for IDH1/2 mutation prediction with standardization and application of dimension reduction that was also applicable to multiple hospitals. Our results demonstrated that overfitting may occur when an ML method providing the highest accuracy in a small training dataset is used for different heterogeneous data sets, and suggested a promising process for developing an ML method applicable to multiple cohorts.

Entities:  

Keywords:  IDH; MGMT; glioma; machine learning; radiogenomics

Year:  2021        PMID: 34298824     DOI: 10.3390/cancers13143611

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

Review 1.  Application of non-negative matrix factorization in oncology: one approach for establishing precision medicine.

Authors:  Ryuji Hamamoto; Ken Takasawa; Hidenori Machino; Kazuma Kobayashi; Satoshi Takahashi; Amina Bolatkan; Norio Shinkai; Akira Sakai; Rina Aoyama; Masayoshi Yamada; Ken Asada; Masaaki Komatsu; Koji Okamoto; Hirokazu Kameoka; Syuzo Kaneko
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

2.  AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?

Authors:  Luca Pasquini; Antonio Napolitano; Martina Lucignani; Emanuela Tagliente; Francesco Dellepiane; Maria Camilla Rossi-Espagnet; Matteo Ritrovato; Antonello Vidiri; Veronica Villani; Giulio Ranazzi; Antonella Stoppacciaro; Andrea Romano; Alberto Di Napoli; Alessandro Bozzao
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

Review 3.  Brain Tumor Characterization Using Radiogenomics in Artificial Intelligence Framework.

Authors:  Biswajit Jena; Sanjay Saxena; Gopal Krishna Nayak; Antonella Balestrieri; Neha Gupta; Narinder N Khanna; John R Laird; Manudeep K Kalra; Mostafa M Fouda; Luca Saba; Jasjit S Suri
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

4.  Fully Automated MR Based Virtual Biopsy of Cerebral Gliomas.

Authors:  Johannes Haubold; René Hosch; Vicky Parmar; Martin Glas; Nika Guberina; Onofrio Antonio Catalano; Daniela Pierscianek; Karsten Wrede; Cornelius Deuschl; Michael Forsting; Felix Nensa; Nils Flaschel; Lale Umutlu
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.